Treatment with recombinant interferon-α2a for patients with chronic hepatitis C: Predictive factors for biochemical and virologic response

Scandinavian Journal of Gastroenterology

Volumn 31, Issue 10, 1996, Pages 1021-1026

  Hagiwara, H ^b   Hayashi, N ^a   Kasahara, A ^b   Oshita, M ^b   Katayama, K ^b   Kato, M ^b   Masuzawa, M ^b   Fusamoto, H ^b   Sakurai, M ^b   Kamada, T ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

chronic hepatitis C; hepatitis C virus RNA level; interferon therapy; predictive factor; single strand conformation polymorphism analysis

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEROTYPING; VIRUS;

EID: 10144235478     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609003123     Document Type: Article

References (22)

1. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A. non-B hepatitis. Science 1989;244:362-4.
2. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transtusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321: 1494-500.
3. Hopf U, Moller B, Kuther D, Stemerowicz R, Loheck H, Ludtke-Handjery A, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990;10:69-76.
4. Hagiwara H, Hayashi N, Mita E, Hiramatsu N, Ueda K, Takehara T, et al. Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease. Gastroenterology 1992;102:692-4.
5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant Interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
6. Di Bisccglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind. placebo-controlled trial. N Engl J Med 1989;321:1506-10.
7. Sacz-Royuela F, Porres JC, Moreno A, Castilio I, Martinez G, Galiana F, et al. High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991;13:327-31.
8. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for Interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
9. Shindo M, Di Bisceglie AM, Cheung L, Shih JWK, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991:115:700-4.
10. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992;15:37-41.
11. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
12. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39: 977-82.
13. Lau JYN, Davis GL, Kniffen J, Qian K-P, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
14. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
15. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in palients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
16. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to Interferon therapy in viremic patients. Hepatology 1992; 16: 619-24.
17. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, et al. Influence of viral quasispecies on effectiveness of Interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
18. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to Interferon therapy. Gastroenterology 1995;108:789-95.
19. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991;1:431-5.
20. Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993;17:545-50.
21. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-53.
22. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.